Vazkepa is a new active substance, made up of a highly purified omega-3 fatty acid and is the first in this class to be issued a NICE recommendation for CV risk reduction. Having been granted this recommendation, Vazkepa could potentially benefit over one million people living in England who have been placed at high risk of a subsequent CV episode, eg a second heart attack.
In England, more than six million people live with CVD, which costs the NHS an estimated £7.4bn per year. While available treatments have helped in reducing the risk of future CV events, more than 137,000 people continue to die from CVD every year…
